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Abstract
Involution of the mammary gland is an essential process that
removes the milk-producing epithelial cells when they become
redundant at weaning. It is a two-step process that involves the
death of the secretory epithelium and its replacement by adipo-
cytes. During the first phase, remodelling is inhibited and apoptotic
cells can be seen in the lumena of the alveoli. In the second phase,
apoptosis is accompanied by remodelling of the surrounding
stroma and re-differentiation of the adipocytes. Considerable effort
has been directed towards understanding the molecular
mechanisms of the involution process and this has resulted in the
identification of the principal signalling pathways involved.
Introduction
The mammary gland is a complex, highly specialised tissue
that has evolved to provide nutrition for the young. The
stunning capacity of the mammary gland to produce milk is
matched by the spectacular manner in which the milk-
producing epithelial cells are removed when they are no
longer required. The mechanism responsible for the
destruction of the secretory epithelium is apoptosis, a form of
programmed cell death that occurs in all multicellular animals.
Since the first description of cell death by Ludwig Gräper in
1914 [1] and the coining of the term apoptosis (Greek for
falling leaves) by Kerr, Wyllie and Currie in 1972 [2], the
genetics and biochemistry of apoptosis have been extensively
studied [3]. It is now apparent that there are variations in the
morphological events associated with cell death and these
probably reflect distinct molecular mechanisms. To date, 10
genetically programmed cell death pathways have been
defined that occur in different situations and in response to
diverse stimuli [4]. Cell death is essential during embryonic
development for organogenesis and tissue sculpting and to
maintain cellular homeostasis in adult organisms. Importantly,
while excessive apoptosis can lead to degenerative diseases,
insufficient apoptosis can result in cancer. Thus, the study of
apoptosis in the mammary gland is important for
understanding both the normal biology of post-lactational
regression and the events leading to breast tumourigenesis.
The physiology and genetics of apoptosis are easily studied
in the mouse mammary gland. Most of the secretory
epithelium is removed within 6 days of weaning in the mouse
and the gland is then remodelled to a pre-pregnant state in
preparation for a subsequent pregnancy. The study of
apoptosis in the mouse mammary gland has been facilitated
by using a forced weaning protocol in which the suckling
pups are removed when they are about 10 days old, at the
peak of lactation and prior to a natural wean. This precipitates
a synchronous involution and allows the study of the
molecular mechanism(s) involved and the morphological
features associated with these molecular events. Forced
involution and glucocorticoid administration studies revealed
two phases of involution: a first phase that lasts for 48 hours
and is reversible; and a second phase that initiates a
remodelling programme that returns the gland to a pre-
pregnant state [5]. Thus, if pups are returned to the mother
within 48 hours, apoptosis is halted and lactation re-
commences. Using teat-sealing, it was demonstrated that the
first phase is regulated by local factors within the individual
gland and not circulating hormones [6,7] while the second
phase is dependent on circulating factors and can be halted
by the administration of glucocorticoid [5,8], possibly through
maintenance of tight junctions [9]. The remodelling phase is
also dependent on the activity of specific matrix metallo-
proteases (MMPs) whose function is blocked in the first
phase by expression of tissue inhibitors of metalloproteases
(TIMPs) [10]. Therefore, in any study of involution, it is
important to consider the timing of events and to put these in
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the context of the two distinct phases of the involution
process.
In recent years, sophisticated genetic approaches have
allowed us to identify the essential components of the two
phases of involution. It is possible to abolish first phase
apoptosis or second phase remodelling, or to shorten the first
phase by accelerating the rate of apoptosis. More and more
genes are being implicated in apoptosis regulation during
involution. The majority of these are likely to be downstream
components of the signalling pathways that are essential
regulators of involution, and thus may have a minor role to
play in the overall process. In this review, therefore, I will
summarise primarily genetic studies that have shed light on
the events and signalling pathways that are critically involved
in initiating and controlling apoptosis. It is clear that the
overall process is highly complex, so only the principal events
will be discussed here. A more extensive review can be found
in [11].
The first phase of involution: 
an apoptosis-only event
Several signalling pathways have been implicated in first
phase involution. The use of genetically modified mice, and
particularly the advent of tissue-specific gene deletion, has
revealed a number of factors that either promote, or delay,
involution and apoptosis. These include members of the
Bcl-2 family: deletion of the anti-apoptotic Bcl-x gene
accelerates apoptosis while loss of the pro-apoptotic Bax
protein delays involution [12,13]. Many of these factors make
a minor contribution to the involution process, however, either
because of redundancy or because they are not essential
components of the primary regulatory pathways. One of these
primary pathways is the Janus kinase (Jak)/signal transducer
and activator of transcription (Stat) pathway, which is
activated in response to cytokines and growth factors,
resulting in the phosphorylation and dimerisation of specific
Stat molecules that translocate to the nucleus and activate
transcription of their target genes. While Stat5 is important
for lobuloalvoelar development [14], Stat3 is critical for the
initiation of apoptosis and involution [15,16]. In the absence
of Stat3, apoptosis is dramatically repressed and the first
phase is abolished. It is now known that the cytokine
leukaemia inhibitory factor (LIF) is the activator of Stat3 in
vivo [17,18] and a number of downstream target genes of
Stat3 have been identified [15,19]. Recently, two of these
targets, IGFBP-5 and c/ebpδ, have been shown to be
important in the apoptotic response in mammary gland
[20,21] and the diminished involution in e/ebpδ-deficient
mammary glands lends further support to the primary function
of the LIF/Stat3 axis. Interestingly, apoptosis can be
suppressed in the presence of constitutively active serine/
threonine kinase Akt/protein kinase B (Akt/PKB) [22],
suggesting that phosphorylated (p)Akt provides an over-
riding survival signal. This is further supported by a recent
study showing that Stat3 induces the expression of negative
regulatory subunits of PI(3) kinase, resulting in diminished
levels of pAkt [23]. This suggests that pAkt is a molecular
sentinel for survival/death signals in mammary epithelium.
This is clearly not the whole story, as other pathways feed
into Akt and will affect the outcome of Stat3 signalling. One
such pathway is the nuclear factor (NF)-κB/IκB kinase
(IKK)/death receptor (DR) pathway, which has recently been
shown to regulate apoptosis and involution in mammary
gland, probably through transcriptional regulation of the DR
ligands tumour necrosis factor (TNF)α and tumor necrosis
factor-like weak inducer of apoptosis (TWEAK) (FO Baxter,
PJ Came, K Abell, B Kedjouar, M Huth, K Rajewsky, M
Pasparakis, CJ Watson, submitted).
Apoptosis in mammary gland has been studied since 1986.
Most previous work focussed on apoptosis at days 2 and 3 of
involution, however, as this is when the most terminal
deoxynucleotidyl transferase nick end labelling (TUNEL)
positive cells were seen. However, it is now clear that the
initial apoptotic signals are much earlier in the involution
process. LIF transcription is induced 30-fold within 12 hours
of forced weaning [17] and microarray data from 2
independent studies [24,25] reveals a cluster of genes that
are transcriptionally upregulated between lactation and
12 hours involution and subsequently decline by 24 hours.
Some of these genes encode DR ligands such as TNF,
TWEAK and FasL. Furthermore, expression of transforming
growth factor (TGF)β3 is induced within 8 hours of forced
weaning, and triggers phosphorylation of Stat3 [26]. Genetic
evidence from TGFβ3 deficient mice further suggests that
this ligand is important for initiating involution.
Morphologically, the first phase is marked by the detachment
of cells from the alveolar structures and shedding into the
lumen. It is known that some cells are shed during lactation.
However, the accumulation of shed cells is not apparent
before 9 hours of forced weaning, whereupon there is a
dramatic increase in shed, caspase-3 positive cells by
12 hours (CJ Watson, unpublished data). This suggests that
there is an initial apoptotic signal within a few hours of forced
weaning that elicits the death programme in a considerable
number of cells. Interestingly, while some alveoli contain 5 to
10 shed cells, others have none. This may indicate that
individual alveoli have different concentrations of factors in
the accumulated milk, or that apoptotic cells induce apop-
tosis in their neighbours, perhaps by secreting a pro-
apoptotic cytokine. It is worth noting that active (cleaved)
caspase-3, a definitive marker of apoptosis, is observed only
in the shed cells at 12 and 24 hours involution and not in the
alveolar wall until 72 hours (CJ Watson, unpublished data).
Thus, it is possible that cells are detached from their
neighbours and expelled into the lumen where they die from
anoikis and a lack of survival signals. However, it is more likely
that the apoptosis programme is initiated before the cells
detach but that cleavage of caspase-3 does not occur until
the cell has been removed from the epithelial layer.
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These data and observations can be combined to illuminate
the initial events in involution (Figure 1). In response to
withdrawal of the suckling stimulus, milk accumulates and this
induces the expression of LIF, TGFβ3 and DR ligands that in
turn trigger the induction of apoptosis through the death
receptor pathway and the Jak/Stat pathway. Downstream
targets of this pathway are upregulated and these ensure the
transition to the second phase. A delay of several hours is
required for the expression of these ligands. This does not
exclude the possibility that concentrations of cytokines and
chemokines that are normally secreted in the milk may
increase due to stasis and could also contribute to the
earliest events.
The second phase of involution: death and
destruction
The architecture of the gland is not changed during the first
phase. Post 48 hours when the transition to the second
phase occurs, however, the alveoli start to collapse and
adipocytes begin to re-fill. Important regulators of these
processes are MMPs and serine proteases that break down
the extra-cellular matrix and activate plasminogen, respec-
tively, resulting in a second wave of apoptosis and tissue
remodelling [10]. The MMPs are primarily expressed by the
stromal cells and MMP2, MMP3 and MMP9 are upregulated
during involution, when their function is to remodel the matrix.
Removal of the matrix induces apoptosis of the epithelial cells
[27] and thus the MMPs have a dual role as initiators of
apoptosis and as remodellers of gland architecture. Thus, if
MMPs are activated on cue, cells that have failed to respond
to first phase apoptotic signals will still be induced to die by
detachment-induced apoptosis. To maintain the reversibility
of the first phase, it is critically important that MMPs are not
activated until 72 hours. This is achieved by expression of the
cognate inhibitors, TIMPs. TIMP3, an inhibitor of MMP2,
appears to be particularly important as involution is
accelerated in TIMP3-deficient mammary glands [28] and first
phase reversibility is lost. Concomitant with the loss of the
mammary epithelium through apoptosis, the surrounding
adipocytes differentiate, a process requiring both plasmin and
MMP3 [5,29]. In the absence of plasminogen, involution is
delayed and this is accompanied by abnormal differentiation
of adipocytes [30] in a process that requires kallikrein [31].
However, the role of adipogenesis and how it is regulated
during remodelling is incompletely understood and much
remains to be learned about this essential process.
Finally, phagocytosis is an important constituent of the
remodelling process. This may involve both autophagy and
phagocytosis by professional and non-professional phago-
cytes due to the large number of cells and debris that have to
be removed [32]. Recently, it has been shown that the
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Figure 1
Signalling events in involution. Milk stasis induces the expression of leukaemia inhibitory factor (LIF) and transforming growth factor (TGF)β3 within
12 hours of forced weaning. These, in turn, phosphorylate and activate the transcription factor Stat3. This results in the induction of apoptosis and
shedding of dying cells into the alveolar lumen. Neighbouring cells migrate to close the gap and maintain the integrity of the alveolar structure.
Concurrently with these events, members of the death receptor ligand family and their receptors are transcriptionally upregulated and this induces
apoptosis through activation of caspase 8. Downstream targets of these pathways are then induced and ensure the transition to the second phase.
Following this reversible first phase, matrix metalloproteases (MMP) begin to break down the ECM surrounding each alveolus, resulting in
detachment induced apoptosis and collapse of the alveoli. Remodelling is then completed by re-differentiation of the adipoctyes which requires the
action of plasmin and MMP3. Full involution returns the gland to a pre-pregnant state. ECM, extracellular matrix.
secreted glycoprotein milk fat globule epidermal growth
factor (EGF) factor 8 (MFG-E8), which binds to apoptotic
cells by recognizing phosphatidylserine, is essential for normal
second phase involution and the clearance of milk fat
globules [33]. Inflammatory mediators that are activated
earlier in involution probably signal the influx of macrophages
that are seen in increased numbers at day 4 involution [25].
This is balanced by anti-inflammatory mediators to prevent
overt inflammation [24,25]. This balance appears to be
skewed in the absence of Stat3, as mastitis and inflammatory
cells are seen in Stat3 deficient mammary glands [15]. It is
noteworthy that NF-κB is also involved in inflammatory
responses and it is conceivable that these two signalling
pathways not only moderate the death/survival balance but
also the inflammatory response.
It is perhaps timely to re-appraise earlier data on apoptosis
and involution in light of recent technological advances that
have allowed more precise characterisation of the process. In
particular, measuring the number of apoptotic cells may be
misleading since it is not known how quickly these are
removed and the rate of phagocytosis may differ between
first and second phases, depending on the number of
phagocytes present. It is worth noting that if DNA is
hypercompacted or degraded by phagocytes, it will no longer
be detectable by the TUNEL assay and so misleading results
could be obtained.
Conclusion
Many pieces of the involution jigsaw are now in place. The
core signalling programmes that regulate apoptosis are well
understood. There are, however, details still to be completed.
For example, the roles of specific components of the apop-
totic machinery have not been comprehensively addressed.
Although a number of caspases, both initiator and
executioner, have been shown to be cleaved and activated
during involution [34], nothing is known with regard to
redundancy and kinetics. The morphology of apoptotic cells
is different in the first and second phases, and it is
reasonable to expect that the apoptotic mechanisms differ in
these phases. Microarray data supports the notion that
second phase apoptosis is most likely mediated by the
classic mitochondrial pathway [24].
Future work will need to address a number of outstanding
questions. What are the earliest signals? What is the
mechanism of the transition from reversible to irreversible
phase? Which downstream components of the signalling
pathways are the critical effectors? And how are the stem
cells protected from apoptosis? These are challenging tasks
and we are still some way from a detailed understanding of
the involution process. The devil may well be in the detail.
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